Secondary Logo

Institutional members access full text with Ovid®

Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy

Makis, William, MD; McCann, Karey, BScN; Riauka, Terence A., PhD; McEwan, Alexander J.B., MD

doi: 10.1097/RLU.0000000000000891
Interesting Images

A 56-year-old man presented with a history of 2 prior resections of a recurrent pancreatic glucagonoma in the past 4 years. Workup revealed new liver and abdominal nodal metastases with a rising serum glucagon level. He was started on peptide receptor radionuclide therapy with 177Lu DOTATATE, and his disease stabilized, while his glucagon levels decreased and also stabilized. After 4 induction and 2 maintenance cycles, he remains progression free for 23 months.

From the Department of Diagnostic Imaging, Cross Cancer Institute, Edmonton, Alberta, Canada.

Received for publication January 7, 2015; revision accepted May 10, 2015.

Conflicts of interest and sources of funding: none declared.

Correspondence to: William Makis, MD, Department of Diagnostic Imaging, Cross Cancer Institute, 11560 University Ave NW, Edmonton, Alberta, T6G 1Z2, Canada. E-mail:

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.